Nicola A. Thompson
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types.
Journal: Nature genetics
Published: November 28, 2023
The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Journal: BMC cancer
Published: November 09, 2021
Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
Journal: BJU international
Published: September 22, 2021
Comprehensive prediction of robust synthetic lethality between paralog pairs in cancer cell lines.
Journal: Cell systems
Published: April 19, 2021
The rise and rise of protein degradation: Opportunities and challenges ahead.
Journal: Drug discovery today
Published: December 23, 2020
Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm.
Journal: Therapeutic advances in medical oncology
Published: October 22, 2020
Combinatorial CRISPR screen identifies fitness effects of gene paralogues.
Journal: Nature communications
Published: April 09, 2020
Mutations in FAM50A suggest that Armfield XLID syndrome is a spliceosomopathy.
Journal: Nature communications
Published: May 30, 2019
A lentiviral vector-based insertional mutagenesis screen identifies mechanisms of resistance to MAPK inhibitors in melanoma.
Journal: Pigment cell & melanoma research
Published: November 06, 2017
Synthetic lethality: emerging targets and opportunities in melanoma.
Journal: Pigment cell & melanoma research
Published: October 19, 2016
Last Updated: 09/26/2026